Global Factor VIII Deficiency Treatment Market 2017-2021

Table of Contents

PART 01: Executive summary

PART 02: Scope of  the report

• Market overview
• Top-vendor offerings

PART 03: Market research methodology

• Research methodology
• Economic indicators

PART 04: Introduction

• Key market highlights
• Highlights

PART 05: Deficiency overview

PART 06: Pipeline analysis

PART 07: Market landscape

• Market overview
• Five forces analysis

PART 08: Market segmentation by type of disease application

• Global hemophilia A drugs market
• Global hemophilia A inhibitors treatment market
• Global von Willebrand disease treatment market

PART 09: Market segmentation by type of therapy

• Recombinant therapies
• Plasma-derived therapies

PART 10: Market segmentation by type of disease management

• Prophylaxis
• On-demand therapy
• Inhibitor therapy

PART 11: Geographical segmentation

• Factor VIII deficiency treatment market in Americas
• Factor VIII deficiency treatment market in EMEA
• Factor VIII deficiency treatment market in APAC

PART 12: Market drivers

• Increasing adoption of prophylactic drugs
• Paradigm shift toward the development of drugs with extended half-life
• Large patient pool driving the shipments of factor VIII units

PART 13: Impact of drivers

PART 14: Market challenges

• Low diagnosis rate affecting the market growth
• High entry barriers
• Cost-intensive complex treatment

PART 15: Impact of drivers and challenges

PART 16: Market trends

• Increase in technological innovations
• Development of gene therapy products
• Expansion initiatives of vendors fueling the market growth
• Increasing investments of vendors to improve the production capability

PART 17: Vendor landscape

• Competitive scenario

PART 18: Key vendor analysis

• Bayer HealthCare
• CSL
• Grifols
• Novo Nordisk
• Pfizer
• Shire
• Other prominent vendors

PART 19: Appendix

• List of abbreviation